

TABLE S1. Characteristics of patients with recurrence

No	Age/ gender	pTNM	Type of TC	Recurrence type	Recurrence site	Time to recurrence, years	Aspirate-Tg [ng/mL]	Serum Tg level [ng/mL]	aTg	Positive findings at detection	Treatment	End of follow- up findings
1	32/F	T1aN0M0	PTC	Structural	Left lobe	9	-	25.22/LT4 stab.	N	US/FNAC	Surgery, RAI	NED
2	37/F	T1aN0M0	PTC	Structural	Left lobe	12	-	4.25/LT4 stab.	N	US/FNAC	No agree to surgery	Structural incomplete
3	50/F	T1aN0M0	PTC	Structural	Right lobe	8	-	2.88/LT4 stab.	N	US/FNAC	Surgery, RAI	NED
4	29/F	T1aN0M0	PTC	Structural	Left lobe	8	-	1.82/LT4 stab.	N	US/FNAC	Surgery, RAI	NED
5	24/F	T1aN0M0	PTC	Structural	Left lobe	2	-	6.7/LT4 stab.	N	US/FNAC	Surgery, RAI	NED
6	39/F	T1aN0M0	PTC	Structural	LN	6	>300	9.62/LT4 stab.	N	US/FNAC	Surgery, RAI	NED
7	31/F	T1aN0M0	PTC	Structural	Thyr bed, LN	5	-	3.31/LT4 ↑	N	US/FNAC	Surgery, RAI	NED
8	57/M	T1aNxM0	PTC	Structural	Thyr bed	3	-	0.04/LT4 2.44/rhTSH ↑	N	WBS- Thyr	RAI	NED
9	53/F	T1aNxM0	PTC	Structural	Thyr bed	16	>300	0.21/LT4 stab.	N	US/FNAC	RAI	Structural incomplete
10	28/F	T1amNxM0	PTC	Structural	LN	5	>300	<0.2/LT4 1.1/rhTSH ↑	N	US/FNAC	Surgery, RAI	NED
11	35/F	T1aN1aM0	PTC	Structural	LN	4	>300	<0.20/LT4	↑	US/FNAC	Surgery, RAI	NED

12	41/F	T1bNxM0	PTC	Structural	Thyr bed	6	<0.20	<0.20/LT4	N	US/FNAC	Surgery	NED
13	52/M	T1bN0M0	PTC	Structural	Thyr bed	4	>300	3.44/LT4 ↑	N	US/FNAC	Surgery	NED
14	27/F	T1bNxM0	PTC	Structural	LN	4	118.4	2.45/LT4 ↑	N	US/FNAC	Surgery, RAI	NED
15	44/F	T1bN0M0	PTC	Structural	Thyr bed	4	>300	<0.2/LT4	↑	US/FNAC	Surgery, RAI	NED
16	54/F	T1bmN0M0	PTC	Structural	Thyr bed	3	>300	<0.2/LT4	N	US/FNAC	Surgery, RAI	NED
17	34/F	T1bmN1M0	PTC	Structural	LN	5	>300	0.13/LT4	N	US/FNAC	Surgery, RAI	NED
18	45/F	T1bN1M0	PTC	Structural	LN	2	>300	<0.2/LT4	N	US/FNAC	Surgery, RAI	NED
19	36/F	T1bN0M0	PTC	Structural	LN	4	>300	2.0/LT4 ↑	↑	US/FNAC	Surgery, RAI	NED
20	59/M	T1bmN0M0	PDTC	Structural	M1-Th2, LN	2	>300	2,37/LT4 6,9/rhTSH ↑	N	FDGPET, CT US/FNAC	RAI	Structural incomplete
21	54/F	T1bN1M0	PTC	Structural	Thyr bed	7	22.80	<0.04/LT4	N	US/FNAC	Surgery, RAI	NED
22	58/F	T1bmN1M0	PTC	Structural	LN	3	>300	<0.2/LT4	↑	US/FNAC	Surgery, RAI	NED
23	34/F	T1bmN1aM0	PTC	Structural	LN	5	>300	<0.04/LT4	N	US/FNAC	Surgery, RAI	NED
24	60/F	T2N1M0	PTC	Structural	Thyr bed	4	-	<0.20/LT4	↑ ↑	US/FNAC	Surgery, RAI, RTh	Death no TC (indeterminate)
25	52/F	T2N1M0	PTC	Structural	Thyr bed, LN	14	>300	<0.20/LT4 1.46/rhTSH ↑	N	US/FNAC	Surgery	NED
26	53/F	T3aN0M0	FTC	Structural	M1-Lung	5	-	3.38/LT4 ↑	N	FDGPET Hist-lung	TKI	Structural incomplete
27	56/F	T3N1M0	PTC	Structural	Thyr bed	8	<0.2	<0.2	N	US/FNAC	RAI	Death no TC

										WBS		NED
28	58/M	T3aN0M0	OTC	Structural	Thyr bed, M1 Th5	3	<0.2	<0.2/LT4	N	US/FNAC	Surgery bed and Th5/RAI, Rth	Structural incomplete (Death no TC)
29	60/F	T3aNxM0	FTC	Structural	M1-Lung	5	-	2.15/LT4 26.0/rhTSH ↑	N	FDGPET	RAI	Structural incomplete
30	76/F	T3aNXM0	PDTC	Structural	Thyr bed	8	-	1.28/LT4 ↑	N	WBS	RAI	Death no TC indeterminat e
31	62/F	T3bNxM0	PTC	Structural	M1 Lung	11	-	1.1/LT4 6.64/rhTSH ↑	N	FDGPET	RAI	Death no TC (structural incomplete)
32	58/F	T3bmN1M0	PTC	Structural	LN	4	9.58	0.05/LT4	N	US/FNAC	Surgery	NED

F- female; M-male; TNM- tumor node metastasis; PTC- papillary thyroid cancer; FTC- follicular thyroid cancer; OTC- oncocytic thyroid cancer; PDTC- poorly differentiated thyroid cancer; Thyr bed- thyroid bed; LN- lymph node; Th- thoracic bone metastases; LT4- on levothyroxine treatment; rhTSH- on recombinant human TSH stimulation; stab. – stable level; US- ultrasound examination; FNAC- fine needle aspiration cytology; FDGPET- Fluorine-18-fluorodeoxyglucose positron emission computed tomography; WBS- whole body scan with 131 I; RAI – radioiodine therapy; NED- no evidence of disease; TC- thyroid cancer